Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS

NCT00232297 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Arrhythmia
Tachycardia, Ventricular
Ventricular Fibrillation

Interventions

DRUG: SSR149744C

Sponsor

Sanofi